Lauren Santye, Assistant Editor

Biovica’s DiviTum assay offers noninvasive tool to monitor efficacy of CDK4/6 inhibitors.

Top news of the day from across the health care landscape.

Report from Magellan Rx Management shows high-cost specialty drugs require effective management of the medical benefit.

Medical pharmacy trend report shows significant impact from specialty drugs.

Combination treatment produces a complete response in mice with epithelial cancer.

Combination therapy targets tumors in epithelial cancer.

Grant E. Knowles, PharmD, discusses how the projected growth in specialty drug spending may change the patient experience in the years ahead.

Toxin produced by cigarette smoke accelerates the growth of tumors.

Top news of the day from across the health care landscape.

Osimertinib (Tagrisso) approved for metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer.

Tyrosine kinase inhibitor improves survival in patients with rare lung cancer.

Ambitious project marks new era for pancreatic cancer patients, investigators say.

Top news of the day from across the health care landscape.

Sirukumab is a human monoclonal antibody that selectively binds to the interleukin-6 cytokine with high affinity in RA.

Suzette DiMascio, CHE, CMCE, CPC, president and CEO of CSI Specialty Group, discusses how to optimize a drug adherence program in specialty pharmacy.

Chronic oral dosing of HIV treatments can have significant complications caused by high pill burden.

Some stakeholders point to a need to reexamine the FDA’s policies and practices to support public transparency.

Hodgkin lymphoma cancer survivors are 2.4 times more likely to develop a second type of cancer.

Research seeks to improve the impact of household-based HIV testing and the link to care by community HIV care providers.

Scientists identify specific genes that cooperate with a well-known tumor suppressor gene.

The smartphone hit the shelves recently.

Study identifies 2 immune system molecules that may play a key role in drug-resistance.

The cytokines interleukin 1 beta (IL1β) and tumor necrosis factor alpha (TNFα) help the spread of drug-resistant cancer.

The rheumatoid arthritis (RA) drug market is projected to reach approximately $28.5 billion by 2025.

Current treatment options for MS help limit relapses, but are unable to reverse the damage the disease has already caused.

Baby Boomer age group testing levels for hepatitis C virus remained very low.

Study identifies potential Achilles heel of kinase-driven cancers.

Majority of patients were free from local recurrence after 1 year of reirradiation with an advanced form of proton therapy.

Top news of the day from across the health care landscape.

The multiple sclerosis (MS) community eagerly awaited the March 28 FDA approval of ocrelizumab (Ocrevus) for treating relapsing and primary progressive forms of MS. -